|
Efficacy and tolerance of systemic therapies in metastatic melanoma of unknown primary versus known cutaneous: A multicenter retrospective study from the MelBase French Cohort. |
|
|
No Relationships to Disclose |
|
|
Employment - Sanofi Pasteur (I) |
Stock and Other Ownership Interests - Sanofi (I) |
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); MSD (Inst) |
Speakers' Bureau - Bristol-Myers Squibb (Inst); MSD (Inst) |
Research Funding - Bristol-Myers Squibb (Inst); Merck Sharp & Dohme (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb |
|
|
No Relationships to Disclose |
|
|
Research Funding - Innate Pharma (Inst); Novartis (Inst) |
Travel, Accommodations, Expenses - Novartis |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre |
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Pierre Fabre |
Travel, Accommodations, Expenses - Bristol Myers Squibb Foundation; MSD; Pierre Fabre |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb/Medarex; Novartis; Pierre Fabre |
Research Funding - MSD Oncology (Inst) |
|
|
Consulting or Advisory Role - Amgen; BMS; Merck KGaA; MSD Oncology; Novartis; Philogen; Pierre fabre; Roche; Roche/Genentech; Sanofi; Sun Pharma |
Speakers' Bureau - Novartis |
Travel, Accommodations, Expenses - BMS; MSD Oncology; Novartis; Pierre Fabre |
|
|
Consulting or Advisory Role - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Roche/Genentech; Sanofi |
Research Funding - Pierre Fabre |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Novartis; pierre fabre; Roche |
|
|
Consulting or Advisory Role - MSD; Novartis; Pierre Fabre; Sanofi |
Research Funding - MSD (Inst) |
Travel, Accommodations, Expenses - MSD Oncology; Novartis; Pierre Fabre |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Consulting or Advisory Role - Novartis |
Research Funding - Bristol-Myers Squibb; Merck Sharp & Dohme |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Amgen; Bristol-Myers Squibb; Incyte; MSD; Novartis; Pfizer; Pierre Fabre; Roche |
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Merck Serono; MSD; Novartis; Pierre Fabre; Roche; Sanofi |
Speakers' Bureau - Amgen; Bristol-Myers Squibb; MSD; Novartis; Roche |
Research Funding - Bristol-Myers Squibb (Inst); Roche (Inst) |
Travel, Accommodations, Expenses - Bristol-Myers Squibb; MSD; Novartis; Pierre Fabre; Sanofi |
Other Relationship - Avantis Medical Systems |
|
|
Consulting or Advisory Role - BMS; MSD Oncology; NOVARTIS; Pierre Fabre; Sanofi/Regeneron |
Research Funding - BMS (Inst); LEO Pharma (Inst) |
Travel, Accommodations, Expenses - BMS; Novartis; Pierre Fabre |